GLP-1 on Non-ST-Segment Elevation Myocardial Infarction
|ClinicalTrials.gov Identifier: NCT02577848|
Recruitment Status : Unknown
Verified October 2015 by Chen Wei Ren, MD, Chinese PLA General Hospital.
Recruitment status was: Recruiting
First Posted : October 16, 2015
Last Update Posted : October 19, 2015
|Condition or disease||Intervention/treatment||Phase|
|Myocardial Infarction||Drug: GLP-1 Drug: Placebo||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||90 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Effects of Liraglutide on Left Ventricular Function in Patients With Non-ST-Segment Elevation Myocardial Infarction|
|Study Start Date :||October 2015|
|Estimated Primary Completion Date :||October 2016|
|Estimated Study Completion Date :||October 2016|
Experimental: GLP-1 group
liraglutide (Novo Nordisk, Bagsværd, Denmark); the frequency: Subcutaneous liraglutide were taken daily; duration: 7 days. After admission, the patients were treated with 0.6 mg liraglutide once daily for 2 day, then 1.2 mg liraglutide for another 2 day, and then 1.8 mg liraglutide for 3 days.
GLP-1 were taken daily for 7 days
Other Name: Liraglutide
Placebo Comparator: placebo
placebo (Novo Nordisk, Bagsværd, Denmark); the frequency: Placebo were taken daily; duration: After admission, the patients were treated with 0.6 mg placebo once daily for 2 day, then 1.2 mg placebo for another 2 day, and then 1.8 mg placebo for 3 days.
Placebo were taken daily for 7 days
- left ventricular ejection fractions [ Time Frame: at 3 months ]The primary efficacy endpoint was the effect of liraglutide on left ventricular ejection fractions (LVEF) measured by transthoracic echocardiography at 3 months .
- 6-minute walk distance [ Time Frame: at 3 months ]The change in6-minute walk distance at 3 months after treatment.
- treatment-emergent adverse events [ Time Frame: at 3 months ]Treatment-emergent adverse events (TEAEs): hypoglycaemia, pancreatitis, thyroid cancer
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02577848
|Contact: Wei Ren Chen, M.D.||+firstname.lastname@example.org|
|PLA General Hospital||Recruiting|
|Beijing, Beijing, China, 100853|
|Contact: Yang Shi, M.D. +8610-66876231 email@example.com|
|Principal Investigator: Yu Tang Wang, M.D.|
|Principal Investigator:||zhu Chen||World Health Organization|